<DOC>
	<DOCNO>NCT00255437</DOCNO>
	<brief_summary>The study evaluate safety efficacy new intravenously administer iron drug treat anemia patient chronic kidney disease dialysis .</brief_summary>
	<brief_title>Ferumoxytol Versus Oral Iron Treatment Anemia Non-Dialysis Dependent Chronic Kidney Disease Patients</brief_title>
	<detailed_description>This study evaluate efficacy safety intravenous ( IV ) ferumoxytol compare oral iron treatment anemia non-dialysis dependent CKD patient . Patients randomize receive either two dos 510 mg ferumoxytol within one week 200 mg oral elemental iron daily three week .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>Male female patient ≥ 18 year . Have chronic kidney disease per K/DOQI guideline . No change EPO status study . Baseline hemoglobin ≤ 11.0 g/dl . Women pregnant lactating . Received another investigational drug device within 30 day . Recent parenteral oral iron therapy . Patients active GI bleed acute bleeding within 4 week . Patients cause anemia . Major surgery within 30 day anticipate planned major surgery study . Patients whose EPO status change study . Patients active infection . Recent blood transfusion . Patients know allergy iron product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>